

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Topspin Fund L.P.</u> <hr/> (Last) (First) (Middle) THREE EXPRESSWAY PLAZA <hr/> (Street) ROSLYN NY 11577 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/23/2020	3. Issuer Name and Ticker or Trading Symbol <u>Oric Pharmaceuticals, Inc. [ORIC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B Preferred Stock	(1)	(1)	Common Stock	231,250	(1)	D ⁽²⁾	
Series C Preferred Stock	(1)	(1)	Common Stock	497,809	(1)	D ⁽²⁾	
Series D Preferred Stock	(1)	(1)	Common Stock	314,815	(1)	D ⁽²⁾	
Series B Preferred Stock	(1)	(1)	Common Stock	2,268,750	(1)	I	See footnote ⁽³⁾

1. Name and Address of Reporting Person* <u>Topspin Fund L.P.</u> <hr/> (Last) (First) (Middle) THREE EXPRESSWAY PLAZA <hr/> (Street) ROSLYN NY 11577 <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Topspin Biotech Fund II, L.P.</u> <hr/> (Last) (First) (Middle) THREE EXPRESSWAY PLAZA <hr/> (Street) ROSLYN NY 11577 <hr/> (City) (State) (Zip)
--

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>LG Management, LLC</u>		
(Last)	(First)	(Middle)
THREE EXPRESSWAY PLAZA		
(Street)		
ROSLYN HEIGHTS	NY	11577
(City)	(State)	(Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>GUTHART LEO</u>		
(Last)	(First)	(Middle)
THREE EXPRESSWAY PLAZA		
(Street)		
ROSLYN HEIGHTS	NY	11577
(City)	(State)	(Zip)

Explanation of Responses:

- Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- The shares are held of record by Topspin Fund, L.P. LG Management, LLC, the general partner of Topspin Fund, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.
- The shares are held of record by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.

Remarks:

<u>TOPSPIN FUND, LP, /s/ Leo A. Guthart, Managing Member of the General Partner</u>	<u>04/23/2020</u>
<u>TOPSPIN BIOTECH FUND II, L.P., /s/ Leo A. Guthart, Managing Member of the General Partner</u>	<u>04/23/2020</u>
<u>LG MANAGEMENT, LLC, /s/ Leo A. Guthart, Managing Member</u>	<u>04/23/2020</u>
<u>/s/ Leo A. Guthart</u>	<u>04/23/2020</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.